|
⚲
|
| Keyboard |
| Puissance Capital Management LP
✚
|
|
|---|---|
| CRD # | 175226 |
| SEC # | 801-135328 |
| CIK # | 0001658437 |
| AUM | 45.0 M (2026-01-13) |
| Employees | 2 (50% Investors, 50% Brokers) |
| Fees | |
| Minimum | |
| Phone | 212-878-3702 |
| Address | |
| Source | [IAPD] [EDGAR] [Website] |
| Total AUM ($M) |
|---|
| Fees and Compensation — Form ADV Part 2A (1/13/2026) [Brochure] |
|---|
Item 5 - Fees and Compensation Puissance or its affiliates will receive a management fee and performance-based compensation from Clients. The Firm’s management fee is generally equal to 2.00% of assets under management per annum and performance-based compensation is generally equal to 20% of the appreciation in the net asset value of each account during each year. Fee arrangements may be amended by agreement between Puissance and each Client or investor. The exact compensation structure will be set forth in the relevant investment management agreement with each Client and each investor, as the case may be. Puissance expects that the Funds will be responsible for investment-related expenses (including brokerage (see Item 12 below), as well as their organizational and offering expenses. The expenses charged to any Managed Accounts will be determined on a case-by-case basis. To the extent that Puissance allocates Clients’ capital to money market funds or exchange- traded funds, Clients would indirectly incur similar fees and expenses as these funds in turn pay similar fees and expenses to their investment managers and other service providers. Item 6 - Performance Fees and Side-by-Side Management Puissance or its affiliates will receive performance-based compensation from Clients, which will be based on a percentage of capital appreciation of their assets. Puissance Capital Management LP Form ADV Part 2A The terms of the performance-based compensation may differ among the Clients. This may result in a conflict of interest when allocating opportunities among Clients, as Puissance may have an incentive to favor Clients that have higher performance-based compensation. To avoid such a conflict of interest, Puissance will develop documented procedures for allocating opportunities among Clients, which will not take into account the performance-based compensation. As management fees and performance-based compensation will be based directly on Clients’ net asset values, Puissance may have a conflict of interest in valuing the assets held in Client accounts. Puissance will follow documented valuation policies and consult with each Client’s third-party administrator, as applicable, in order to mitigate this risk. |
| Account Minimums and Types of Clients — Form ADV Part 2A (1/13/2026) [Brochure] |
|---|
Item 7 - Types of Clients Puissance will provide investment advice to clients that are private funds, high net worth individuals or other institutional investors. Investors in the Funds are generally expected to be institutional investors and high net worth individuals that qualify as “accredited investors” (as defined in Rule 501 under the Securities Act of 1933, as amended) and “qualified purchasers” (as defined under the Investment Company Act of 1940, as amended). The minimum initial investment in the Funds is expected to be $500,000, subject to Puissance’s discretion to accept lesser amounts. The minimum initial investment for high net worth individuals is expected to be $100,000. Puissance will determine the minimum investment for a Managed Account on a case by case basis. |
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Scynexis Inc | 1.4 | ||
| Corvus Pharmaceuticals Inc | 0.2 | ||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | PCM AI Opportunities Fund | [2019-03-14] | 1.0 M | 12.0 M |
| Filed 2025-10-27 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| PE | Puissance Cross-Border Opportunities III LLC | 2018-01-25 | 3.0 M | |
| PE | Puissance Cross-Border Opportunities II LLC | 2018-01-25 | 8.3 M | |
| PE | Puissance Cross-Border Opportunities IV LLC | 2018-01-25 | 2.0 M | |
| PE | Puissance Cross Border Opportunities V LLC | 2018-01-25 | 0.2 M | |
| PE | Puissance Life Science Opportunities Fund VII | 2018-01-25 | 0.0 M | |
| HF | Puissance China Market Neutral Master Fund LP | [2017-03-30] | 44.8 M | 1.9 M |
| Filed 2016-03-31 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| PE | Puissance Cross-Border Opportunities I LP | 2017-03-30 | 31.2 M | |
| HF | Puissance Asia Master Fund LP | [2015-07-09] | 10.0 M | 8.5 M |
| Filed 2015-06-02 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $1,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Puissance Capital Master Fund LP | [2015-07-09] | 44.8 M | 80.7 M |
| Filed 2016-03-31 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| View All | ||||
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 33.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 1 | 12.0 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 3 | 45.0 |
| By Discretionary | ||
| Discretionary | 3 | 45.0 |
| Non-Discretionary | 0 | 0.0 |
| Total | 3 | 45.0 |
| By Non-United States Persons | ||
| Non-United States Persons | 45.0 | |
| United States Persons | 0.0 | |
| Total | 3 | 45.0 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Ted Wang | Director, Executive Officer | 19 | 3 | |
| Puissance Capital Fund GP LLC | Executive Officer | 2 | 1 | |
| Puissance Capital Management LP | Executive Officer | 2 | 1 | |
| Hanchen Jin | Director | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001658437] | |
| 3 | [0001658437] | |
| 4 | [0001658437] | |
| SC 13D | [0001658437] |
| Form 13D/13G Filer | Form 13D/13G Subject | Filed |
|---|---|---|
| Puissance Capital Management LP | ViewRay Inc | [2017-01-25] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional, Retail |
| Fund Types | Hedge Fund, Private Equity |
| LEI | 254900XD1KV0Z9RJYC26 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Bellerophon Therapeutics LLC BLPH
Common Stock
|
2023-10-13 | Sell | 1,076,841 | $0.10 | 107,684 |
|
Bellerophon Therapeutics LLC BLPH
Common Stock
|
2023-06-07 | Sell | 134,421 | $0.83 | 111,569 |
|
Bellerophon Therapeutics LLC BLPH
Common Stock
|
2023-05-18 | Sell | 560,000 | $9.46 | 5,297,600 |
|
Bellerophon Therapeutics LLC BLPH
Common Stock
|
2021-06-07 | Grant | 8,189 | $4.00 | 32,756 |
|
Bellerophon Therapeutics LLC BLPH
Warrants (Right to buy) · derivative
|
2021-04-26 | Grant | 380,950 | $0.00 | |
|
Bellerophon Therapeutics LLC BLPH
Warrants (Right to buy) · derivative
|
2021-04-26 | Grant | 304,286 | $0.00 | |
|
Bellerophon Therapeutics LLC BLPH
Common Stock
|
2021-04-26 | Grant | 609,231 | $4.00 | 2,436,924 |
|
ChronoScale Holdings Corp EKSO
Common Stock
|
2020-07-23 | Grant | 7,383 | $0.00 | |
|
Bellerophon Therapeutics LLC BLPH
Common Stock
|
2020-05-21 | Grant | 1,153,846 | $13.00 | 14,999,998 |
|
Bellerophon Therapeutics LLC BLPH
Common Stock
|
2020-04-17 | Other | 553,250 | ||
|
ChronoScale Holdings Corp EKSO
Common Stock
|
2020-03-02 | Other | 8,918,898 | ||
|
ChronoScale Holdings Corp EKSO
Stock Option (right to buy) · derivative
|
2020-01-16 | Grant | 136,496 | $0.00 | |
|
ChronoScale Holdings Corp EKSO
Common Stock
|
2020-01-16 | Grant | 19,445 | $0.45 | 8,750 |
|
Tracon Pharmaceuticals Inc TCON
Common Stock
|
2019-12-09 | Sell | 340,134 | $2.92 | 993,191 |
|
Tracon Pharmaceuticals Inc TCON
Common Stock
|
2019-12-05 | Sell | 43,996 | $3.05 | 134,188 |
|
Tracon Pharmaceuticals Inc TCON
Common Stock
|
2018-11-29 | Buy | 4,326 | $1.13 | 4,888 |
|
Tracon Pharmaceuticals Inc TCON
Common Stock
|
2018-11-29 | Sell | 4,326 | $1.21 | 5,234 |
|
ChronoScale Holdings Corp EKSO
Common Stock
|
2018-08-03 | Grant | 19,179 | $1.79 | 34,330 |
|
ChronoScale Holdings Corp EKSO
Employee Stock Option (right to buy) · derivative
|
2018-08-03 | Grant | 41,000 | $0.00 |
| Comparable Firms | State | AUM |
|---|---|---|
|
Altai Capital Management LP
✚
|
49.8 M | |
|
Remy Investors & Consultants Incorporated
✚
|
CA | |
|
Third Security LLC
✚
|
VA | |
|
BRS Financial LLC
✚
|
AR | |
|
Fortius Financial Advisors LLC
✚
|
UT | |
|
Spruce Investment Advisors LLC
✚
|
CT | |
|
Income Partners Asset Management HK Limited
✚
|
||
|
Red Hook Management LLC
✚
|
NJ | |
|
Summit Capital Management LLC
✚
|
WA | |
|
Prairie Capital Management LLC
✚
|
MO |